cancer-stem-cells-2018-scientifictracks

10 / 38

J u n e 1 1 - 1 3 , 2 0 1 8 | D u b l i n , I r e l a n d
alliedacademies
Page 28
Note:
CANCER STEM CELLS AND
ONCOLOGY RESEARCH
11th International Conference on
Journal of Medical Oncology and Therapeutics | Volume 3
Nitin Telang, J Med Oncl Ther 2018, Volume 3
DRUG RESISTANT STEM CELLS:
MODELS FOR TARGETED THERAPY
OF BREAST CANCER
Nitin Telang
Palindrome Liaisons Consultants, USA
Cancer stem cells represent a subpopulation of the primary cancer that
ispredominantlycharacterizedbydrug resistant phenotypesexhibiting
tumorigenic potential. Long-term treatment options lead to emergence of
drug resistant cancer stem cells. Relevant models for cancer stem cells
facilitate novel experimental approaches that identify efficacy of stem
cell targeted therapeutic agents. Experiments in the present study were
designed to characterize stem cell models from molecular subtypes of
clinical breast cancer.
Nitin Telang has completed his PhD degree in
1974 from University of Poona, India, and ob-
tained his Post-doctoral training (1976-1985)
in the USA at University of Nebraska, American
Health Foundation, New York, and Memorial
Sloan-Kettering Cancer Center, New York. He
served on the Faculty of Memorial Sloan-Ket-
tering Cancer Center, Weill-Cornell Medical
College, and Strang Cancer Prevention Center,
New York (1986-2007). He serves as the Direc-
tor of Cancer Prevention Research Program at
Palindrome Liaisons Consultants, New Jersey.
He has published more than 100 peer-reviewed
papers and serves on the Editorial Boards of
International Journal of Oncology, Oncology Re-
ports and BMC-Complementary and Alternative
Medicine.
BIOGRAPHY